Efficacy and Safety of Apolipoprotein C‐ III Inhibitors in Hypertriglyceridemia: A Network Meta‐Analysis of Randomised Controlled Trials
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70717 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Mohammed A Elbahloul und 10 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Kafr El-Shaikh University, Kafr El Shaikh, Egypt. Hauptthemen laut MEDLINE: Apolipoprotein C-III, Hypertriglyceridemia, Hypolipidemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben.
Abstract (Originalsprache)
Background
Hypertriglyceridemia is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD). We aimed to evaluate the efficacy and safety of apolipoprotein C‐III (ApoC‐III) inhibitors in patients with hypertriglyceridemia.
Methods
Electronic databases were systematically searched for randomised controlled trials (RCTs) comparing ApoC‐III inhibitors (Volanesorsen, Olezarsen and Plozasiran) with placebo. A frequentist network meta‐analysis was performed. Continuous outcomes were presented as mean differences (MDs), and dichotomous outcomes as risk ratios (RRs), both with 95% confidence intervals (CIs).
Results
A total of 15 RCTs involving 3934 patients were included. All ApoC‐III inhibitors demonstrated significant reductions in TG, except for Volanesorsen 100 mg Q1W and Olezarsen 10 mg Q4W. Olezarsen 80 mg administered every 4 weeks had the highest SUCRA ranking for TG reduction (MD: −63.26; 95% CI: −70.04 to −56.47; p < 0.01). Moreover, ApoC‐III inhibitors were associated with a significant reduction in the incidence of pancreatitis (HR: 0.16, 95% CI: 0.07–0.33, p < 0.01). None of the agents significantly increased the risk of serious adverse events.
Conclusions
ApoC‐III inhibitors significantly improved triglyceride levels and other lipid parameters and, most importantly, substantially reduced the risk of acute pancreatitis. Future trials are needed to evaluate their effects on cardiovascular outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Kafr El-Shaikh University, Kafr El Shaikh, Egypt.
- Clinical Pharmacy Department, Faculty of Pharmacy, Deraya University, Minia, Egypt.
- Department of Pathology, National Hospital, Latakia, Syria.
- Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
- Faculty of Medicine, Fayoum University, Fayoum, Egypt.
- Faculty of Medicine, Zagazig University, Zagazig, Egypt.
ORCID-Profile: Mohammed A Elbahloul
Zitieren
APA
Elbahloul, M. A., Gamal, A., Maihoub, O., Elbaz Hassan, M. M., Attia, M. K., Salah, A. M., Elboraay, T., Awad, A. K., Akoum, A., Elazab, A., & Elgendy, I. Y. (2026). Efficacy and Safety of Apolipoprotein C‐ III Inhibitors in Hypertriglyceridemia: A Network Meta‐Analysis of Randomised Controlled Trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70717
Vancouver
Elbahloul MA, Gamal A, Maihoub O, Elbaz Hassan MM, Attia MK, Salah AM, et al. Efficacy and Safety of Apolipoprotein C‐ III Inhibitors in Hypertriglyceridemia: A Network Meta‐Analysis of Randomised Controlled Trials. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70717
BibTeX
@article{Elbahloul2026,
author = {Elbahloul, Mohammed A and Gamal, Aliaa and Maihoub, Odai and Elbaz Hassan, Moustafa M and Attia, Manar Khaled and Salah, Ahmed M and Elboraay, Toka and Awad, Ayman K and Akoum, Atef and Elazab, Ahmed and Elgendy, Islam Y},
title = {Efficacy and Safety of Apolipoprotein C‐ III Inhibitors in Hypertriglyceridemia: A Network Meta‐Analysis of Randomised Controlled Trials},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70717}
}
EUVIMED